Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab

Journal of Cancer Research and Therapeutics

Volumn 5, Issue 2, 2009, Pages 130-132

  Ozen, Alaattin ^a   Cicin, Irfan ^a,b   Sezer, Atakan ^a   Uzunoglu, Sernaz ^b   Saynak, Mert ^a   Genchellac, Hakan ^a   Karagol, Hakan ^b  

^a TRAKYA UNIVERSITY   (Turkey)

^b Faculty of Medicine   (Turkey)

Author keywords

Bevacizumab; Dural sinus vein; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER THERAPY; CASE REPORT; CEREBRAL SINUS THROMBOSIS; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEINURIA; RECTUM BIOPSY; RECTUM CANCER; RECTUM CARCINOMA; SEIZURE; SIGMOID; UNCONSCIOUSNESS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; SINUS THROMBOSIS, INTRACRANIAL;

EID: 67749098105     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.52791     Document Type: Article

References (10)

1. Reidy D, Saltz L. Targeted strategies in the treatment of metastatic ; cancer. J Natl Compr Canc Netw 2007;5:983-90.
2. Health Canada Endorsed Important Safety Information on Avastin (bevacizumab). Available from: http://wwrw.hc-sc.gc.ca/dhp-mps/ alt-formats/hpfb-dgpsa/pdf/medeff/avastin-pc-cp-eng.pdf. [last accessed on 2006 Oct 24].
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
4. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705.
5. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
6. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, et al. Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients. Arterioscler Thromb Vasc Biol 2002;22:1500-5.
7. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542.
8. De Bruijn SF, De Haan RJ, Stam J. Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients: For The Cerebral Venous Sinus Thrombosis Study Group. J Neurol Neurosurg Psychiatry 2001;70:105-8.
9. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35:664-70.
10. Einhäupl K, Bousser MG, de Bruijn SF, Ferro JM, Martinelli I, Masuhr F, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol 2006;13:553-9.